CytRx announced that the FDA has granted multiple Orphan Drug designations to aldoxorubicin for glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin is a modified version of the chemotherapeutic agent, doxorubicin combined with a novel single-molecule linker that binds directly to circulating albumin.
Aldoxorubicin is currently being studied in a pivotal global Phase 3 clinical trial evaluating the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS). CytRx is also evaluating aldoxorubicin in two Phase 2 clinical trials, one in patients with late-stage GBM and the other in HIV-related Kaposi’s sarcoma.
CytRx plans to initiate a global Phase 2b trial in patients with relapsed small cell lung cancer this month and is undertaking a Phase 1b combination study of aldoxorubicin plus gemcitabine as a potential precursor to a trial in relapsed ovarian cancer.
For more information visit CytRx.com.